Press release
Develop business strategies Of Alzheimers Disease - Pipeline Review, H1 2018
About Alzheimers Disease
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.
Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581019
Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.
Request for TOC @ https://www.marketresearchreports.biz/reports/1581019/alzheimers-disease-pipeline-review-h1-2018-market-research-reports/toc
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 23, 50, 56, 1, 253, 99 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 43 molecules, respectively.
Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
View Report @ https://www.marketresearchreports.biz/reports/1581019/alzheimers-disease-pipeline-review-h1-2018-market-research-reports
Table of Contents
Table of Contents 2
Introduction 10
Alzheimer's Disease - Overview 11
Alzheimer's Disease - Therapeutics Development 12
Alzheimer's Disease - Therapeutics Assessment 72
Alzheimer's Disease - Companies Involved in Therapeutics Development 98
Alzheimer's Disease - Drug Profiles 188
Alzheimer's Disease - Dormant Projects 1092
Alzheimer's Disease - Discontinued Products 1123
Alzheimer's Disease - Product Development Milestones 1130
Appendix 1142
List of Tables
Number of Products under Development for Alzheimer's Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Alzheimer's Disease - Pipeline by AB Science SA, H1 2018
Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2018
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2018
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Accera Inc, H1 2018
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2018
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2018
Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2018
Alzheimer's Disease - Pipeline by Alector LLC, H1 2018
Alzheimer's Disease - Pipeline by Allergan Plc, H1 2018
Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Allinky Biopharma, H1 2018
Alzheimer's Disease - Pipeline by ALSP Inc, H1 2018
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2018
Alzheimer's Disease - Pipeline by Alzinova AB, H1 2018
Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2018
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
Alzheimer's Disease - Pipeline by Amgen Inc, H1 2018
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2018
Alzheimer's Disease - Pipeline by Annexon Inc, H1 2018
Alzheimer's Disease - Pipeline by Aphios Corp, H1 2018
Alzheimer's Disease - Pipeline by Apodemus AB, H1 2018
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2018
Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2018
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2018
Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2018
Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2018
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2018
Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H1 2018
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2018
Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H1 2018
Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Axxam SpA, H1 2018
Alzheimer's Disease - Pipeline by AZTherapies Inc, H1 2018
Alzheimer's Disease - Pipeline by Beactica AB, H1 2018
Alzheimer's Disease - Pipeline by Berg LLC, H1 2018
Alzheimer's Disease - Pipeline by BioArctic AB, H1 2018
Alzheimer's Disease - Pipeline by Biogen Inc, H1 2018
Alzheimer's Disease - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H1 2018
Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Co, H1 2018
Alzheimer's Disease - Pipeline by Bsim2, H1 2018
Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Cardax Inc, H1 2018
Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H1 2018
Alzheimer's Disease - Pipeline by Celon Pharma SA, H1 2018
Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2018
Alzheimer's Disease - Pipeline by Clera Inc, H1 2018
Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Cognosci Inc, H1 2018
Alzheimer's Disease - Pipeline by CohBar Inc, H1 2018
Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018
Alzheimer's Disease - Pipeline by ConSynance Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Corium International Inc, H1 2018
Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H1 2018
Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H1 2018
Alzheimer's Disease - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H1 2018
Alzheimer's Disease - Pipeline by Cypralis Ltd, H1 2018
Buy Now @ https://www.researchmoz.com/checkout?rep_id=1581019&licType=S
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Develop business strategies Of Alzheimers Disease - Pipeline Review, H1 2018 here
News-ID: 955751 • Views: …
More Releases from MarketResearchReports.biz
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in…
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume…
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with…
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is…
More Releases for Alzheimer
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Alzheimer Diagnostic Tests Market
GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
